Global Finance News
08 Dec 2025, 20:22
ResMed received FDA clearance for Smart Comfort, an AI-enabled system designed to personalize comfort settings for people beginning CPAP therapy for obstructive sleep apnea. Drawing on more than 100 million nights of anonymized sleep data, the tool uses machine learning to recommend individualized comfort settings through the myAir app when paired with an AirSense 11 device. A limited U.S. beta launch will begin in early 2026.
Smart Comfort aims to improve therapy adherence by addressing early challenges such as mask fit and pressure adjustments, with real-world evidence showing higher engagement among users whose settings matched its recommendations. The feature helps streamline setup for clinicians while supporting patients’ confidence and comfort without altering prescribed therapeutic pressures.
ResMed says the technology reflects its broader strategy of combining AI, connected devices and digital health tools to make sleep therapy more personalized and effective as sleep apnea rates continue to rise in the U.S.
Smart Comfort aims to improve therapy adherence by addressing early challenges such as mask fit and pressure adjustments, with real-world evidence showing higher engagement among users whose settings matched its recommendations. The feature helps streamline setup for clinicians while supporting patients’ confidence and comfort without altering prescribed therapeutic pressures.
ResMed says the technology reflects its broader strategy of combining AI, connected devices and digital health tools to make sleep therapy more personalized and effective as sleep apnea rates continue to rise in the U.S.